The Angiogenesis Foundation Home Page
Edit Page
Report
Scan day: 09 February 2014 UTC
31
Virus safety - good
Description: Provides leading information about new treatment options for cancer patients. The Foundation provides information to cancer patients and their families, including information regarding clinical trials for antiangiogeneic drugs, companies manufacturing these pharmaceuticals, complimentary medicine linked to antiangiogenesis, and FDA-approved drugs with antiangiogenic properties.
Sorafenib (NEXAVAR®) Approved for Treatment of Thyroid Cancer Thyroid cancer has become one of the fastest-increasing cancers in recent years and is the fifth most common cancer in women. There are more than 213,000 new cases of thyroid cancer annually and approximately 35,000 people die from thyroid cancer worldwide each year. The U.S. Food and Drug Administration (FDA) has approved the oral multi-kinase inhibitor sorafenib (NEXAVAR®) for the treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment. This type of thyroid cancer has previously been difficult to treat and some patients are unresponsive to standard therapy.
Size: 714 chars
Contact Information
Email: —
Phone&Fax: —
Address: —
Extended: —
WEBSITE Info
| Page title: | Angiogenesis Foundation |
| Keywords: | |
| Description: | |
| IP-address: | 184.173.235.2 |